Do glycoprotein IIb/IIIa inhibitors interact with assays for myocardial necrosis?
OBJECTIVE
To determine whether glycoprotein (GP) IIB/IIIA inhibitors interact with cardiac marker assays: total creatine kinase (CK), CK-MB, and troponin-I (TnI).


METHODS
Two blood samples were collected during coronary angiography or angioplasty and analyzed for cardiac markers: one after arterial sheath insertion and the second 10 mins later. In the first phase (n=101), heparin and GP IIb/IIIa inhibitors were given between samples, in the second phase (n=45) only heparin was given, and in the third phase (n=54) neither drug was given.


RESULTS
In each phase, there was a significant decline in total CK over the 10 min period. There were no consistent significant changes in CK-MB or TnI.


CONCLUSIONS
Neither GP IIb/IIIa inhibitors nor i.v. heparin interact with cardiac marker assays. There is a small but significant decline in total CK levels within 10 mins of arterial puncture that is unrelated to administration of these drugs.
Cantor
Warren J
WJ
Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada. cantorw@smh.toronto.on.ca
Vandenbroucke
Art
A
Strauss
Bradley H
BH
Chisholm
Robert J
RJ
Young
Kirk
K
Christenson
Robert H
RH
Goldman
Lorne
L
Fitchett
David
D
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000494:pharmacology; D015415:Biomarkers / Q000097:blood; D004347:Drug Interactions / Q000502:physiology; D006493:Heparin / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology; D009206:Myocardium / Q000473:pathology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D006493:Heparin; D000077284:Abciximab